Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

LianBio Cleared to Start China Phase II Trial of FGFR Inhibitor

publication date: Dec 1, 2020

LianBio, a Shanghai-Princeton company, is approved to start a China Phase IIa trial of an FGFR inhibitor, infigratinib. Infigratinib will be tested in patients who have advanced/metastatic gastric cancer or gastroesophageal junction adenocarcinoma with FGFR2 gene amplification. LianBio acquired Greater China rights to infigratinib from QED Therapeutics, a subsidiary of BridgeBio, in a $532 million deal announced in August. The news came as BridgeBio filed a US NDA for infigratinib as a second-line cholangiocarcinoma treatment. More details....

Stock Symbol: (NSDQ: BBIO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.